New active substance reprieve for Genzyme's Aubagio good news for Biogen
This article was originally published in Scrip
Executive Summary
Sanofi/Genzyme will be relieved to hear that the European Medicines Agency's Committee for Medicinal Product for Human Use has, after all, decided to give MS drug Aubagio (teriflunomide) new active substance status. The news not only secures data exclusivity, staving off generic competition, for Aubagio, but could also be a good sign for Biogen Idec. The biotech company is wrangling with the EMA over whether its own MS drug Tecfidera (dimethyl fumarat) qualifies for data exclusivity.